Clinical Trials Directory

Trials / Completed

CompletedNCT04429815

Impact of Smoking and Nicotine on the Risk of Being Infected With COVID-19

Status
Completed
Phase
Study type
Observational
Enrollment
195 (actual)
Sponsor
Central Hospital, Nancy, France · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Several studies have shown that smokers have a higher risk of developing a severe form of COVID-19 once a person has been infected. This is explained by the damage caused by smoking at the bronchopulmonary level and an overexpression of some coronavirus receptors at the pulmonary level when exposed to tobacco. In contrast, recent data indicate that smokers are proportionally less infected with the COVID-19 virus since all available cohort data from around the world show a very low rate of smokers among COVID-19 infected subjects. The mechanisms at the origin of this protective effect are not known. All of these data lead us to question the real role of nicotine in the protective effect of tobacco observed in the general population against infection by the COVID-19 virus. The objectives are : * To show that subjects taking nicotine substitutes as part of a smoking cessation program are less infected with COVID-19 than non-smokers. * To show that active smokers are less infected with COVID-19 than non-smokers. * To compare the percentage of positive serological tests in subjects taking nicotine substitutes to the percentage of positive serological tests in active smokers.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTSerological test for COVID-19.Serological test for COVID-19 performed as part of standard of care.

Timeline

Start date
2020-08-25
Primary completion
2021-05-26
Completion
2021-05-26
First posted
2020-06-12
Last updated
2021-08-17

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04429815. Inclusion in this directory is not an endorsement.